Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 110 of 360 for:    hepatitis b | Open Studies

Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission (TA-PROHM)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2017 by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Sponsor:
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:
NCT02937779
First received: October 17, 2016
Last updated: January 11, 2017
Last verified: January 2017
  Purpose

The World Health Organization recommends that all high endemic countries for HBV infection based their mother to child transmission prevention strategies on vaccination of all children and administration of immunoglobulins (HBIG) to infants born to infected mothers in the first 24 hours after birth. Lack of access to antenatal screening and to HBIG significantly results in failure of this strategy in many countries. Moreover, despite sero-vaccination, 10 to 15% of infants of mothers that are positive for HBsAg and HBeAg are still infected, as high levels of HBV replication occurring in the third quarter of pregnancy act as a major risk factor.

The objective of this study is to assess the effectiveness of an operational strategy to prevent HBV mother-to-child transmission (MTCT) in Cambodia based on the use of rapid tests HBs Ag and HBe Ag to screen HBV infection and a treatment by TDF for patients with a positive HBeAg test with a "test and treat" strategy for those seen for Antenatal Care (ANC) from 24 weeks of amenorrhea. In all cases, vaccination of the newborn will be carried out according to the national protocol in Cambodia i.e. 4 injections at 24 hours, 6, 10 and 14 weeks of age.

A phase IV multicenter observational and interventional non randomized prospective study will be conducted in 4 maternity in Cambodia.

The primary outcome will be the proportion of active HBV infection in new-born at 6 months of life estimated by HBs Ag positivity.

The study will aim to document the acceptability and the operational implementation of the study using rapid tests usable in all health centers and a drug available in all the country thanks to HIV national program. The results will be helpful for Cambodian government in order to implement guidelines and algorithm follow-up for HBV-infected pregnant women.


Condition Intervention Phase
Hepatitis B Chronic Infection
Pregnancy
Drug: Tenofovir disoproxil fumarate
Device: Rapid tests HBe Ag
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission

Resource links provided by NLM:


Further study details as provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):

Primary Outcome Measures:
  • Proportion of active HBV infection in new-born at 6 months of life estimated by HBs Ag positivity [ Time Frame: 6 months post-partum ]

Secondary Outcome Measures:
  • Process and acceptability of the screening phase : Proportion of women with screening proposed among those eligible in antenatal consultation (ANC) [ Time Frame: Enrollement ]
  • Process and acceptability of the screening phase: Proportion of women with a done screening among those to whom screening was proposed [ Time Frame: Enrollement ]
  • Process and acceptability of the screening phase: Proportion of women with a given results in less than one day among those to whom the test was made [ Time Frame: Enrollement ]
  • Process and acceptability of the screening phase: Care-giver satisfaction regarding the strategy (estimated by questionnaires) [ Time Frame: Enrollement ]

Other Outcome Measures:
  • Process and acceptability of the drug's intervention [ Time Frame: Enrollement ]
  • Proportion of women with viral load > 6 Log among those HBe Ag negative [ Time Frame: Enrollement ]
  • Proportion of new-born with positive HBs Ag at 6 months according to treatment duration, initial and delivery viral load level [ Time Frame: 6 months post-partum ]
  • Decrease curve of HBV VL after TDF initiation over time [ Time Frame: From enrollement to 8 weeks or 6 months post-partum ]
  • Occurrence of maternal adverse events including serious adverse events and adverse events grade 3 or 4 [ Time Frame: From enrollement to 6 months post-partum ]
  • Proportion of women needing treatment continuation in post-partum among those to whom treatment was initiated [ Time Frame: 6 weeks post-partum ]
  • Occurrence of acute exacerbation after treatment interruption [ Time Frame: From 8 weeks post-partum to 6 months post-partum ]

Estimated Enrollment: 933
Study Start Date: April 2017
Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HBs Ag positive

tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for positive Hbe Ag women.

No treatment for negative HBe Ag women

Drug: Tenofovir disoproxil fumarate
tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
Other Name: TDF
Device: Rapid tests HBe Ag
For all HBs Ag positive women

Detailed Description:

Principal objective: Assess the effectiveness of a strategy to prevent HBV mother-to-child transmission (MTCT) in Cambodia based on the use of rapid tests HBs Ag and HBe Ag to screen HBV infection and a treatment by TDF for patients with a positive HBeAg test with a "test and treat" strategy for those seen for Antenatal Care (ANC) from 24 weeks of amenorrhea.

Secondary objectives Assess the feasibility and acceptability for patients and health care providers of the rapid tests screening strategy Assess the acceptability of the test and treat strategy for patients seen after 24 weeks of amenorrhea Describe the HBV viral load (VL) decrease caused by the TDF Estimate the rate of HBV transmission to newborns according to the time spent on TDF as well as initial viral load level and delivery viral load level Estimate the rate of HBV transmission to newborns for HBe Ag negative women Describe the correlation between HBV viral load level and HBe Ag status Describe subgroups of mothers and new-borns for which the strategy seems more effective Assess TDF safety in mothers Analyse the cost-effectiveness of the strategy compare to international guidelines (WHO, APASL)

Each woman will be informed of the objectives and the total duration of the study as well as the benefits and risks to participate. An information sheet in Khmer will be given to each woman. The study will be composed of two phases of information's and consent. The first one will be done during the HBs Ag screening using rapid test; the screening will be proposed to all pregnant women attending ANC in one of the affiliated centres. The second phase will be done during the inclusion visit and will concern only HBs Ag positive women. The study will concern only HBs Ag positive women with 1) follow up of all HBsAg positive women from inclusion up to 6 months postpartum 2) For HBeAg positive women, initiation of treatment by fumarate de tenofovir disoproxil (Viread®), with a daily administration of one 300mg pill. Women will be treated from 24 weeks of amenorrhea until 6 weeks post-partum. For women with first ANC after 24 weeks of amenorrhea, treatment will begin the day of inclusion. Treatment will be given for 4 weeks and adherence will be estimated. In all cases, vaccination of the newborn will be carried out according to the national protocol in Cambodia i.e. 4 injections at 24 hours, 6, 10 and 14 weeks of age.

A total of 933 positive HBs Ag pregnant women will be enrolled including 280 HBe Ag positive women and 653 HBe negative women.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • >= 18 years old the day of inclusion
  • Pregnancy
  • Positive HBs Ag
  • Informed consent obtained with information sheet given and explained and the consent form signed by the participant of the project investigator at the latest the day of the inclusion

Exclusion Criteria:

  • Women refusing HBs Ag test
  • HIV co-infection
  • HCV co-infection
  • HBV treatment ongoing at the day of inclusion
  • Creatinine clearance < 30 mL/min
  • Severe gravidic disease present at inclusion involving life threatening to the mother and/or the child
  • Evidence of pre-existing fetal anomalies incompatible with the child's life
  • Imminent child's birth defined as cervix dilatation up to 7 centimeters
  • Intention to deliver in a maternity not linked to the study
  • Any concomitant medical condition that, according to the clinical site investigator would contraindicate participation in the study.
  • Concurrent participation in any other clinical trial without written agreement of the two study teams
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02937779

Contacts
Contact: Olivier SEGERAL, MD +85512479313 oliseg@hotmail.com
Contact: Laurence BORAND, PharmD, PhD +85512333671 lborand@pasteur-kh.org

Sponsors and Collaborators
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Investigators
Principal Investigator: Samsorphea CHHUN, MD Calmette Hospital
  More Information

Responsible Party: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier: NCT02937779     History of Changes
Other Study ID Numbers: ANRS 12345
Study First Received: October 17, 2016
Last Updated: January 11, 2017

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Viral, Human
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Tenofovir
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents

ClinicalTrials.gov processed this record on April 28, 2017